- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03360630
Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC
February 5, 2024 updated by: Jun Ren MD, PhD, Capital Medical University
Autologous Dendritic Cell-cytokine Induced Killer Cell Immunotherapy Combined Anti-PD1 in Advanced NSCLC: A Randomized Controlled Trial
A randomized controlled study to compared the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells administered with anti-PD-1 antibody in advanced NSCLC.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100038
- Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically or cytologically confirmed advanced or metastatic NSCLC.
- Patients must have received previously standard therapy for that malignancy or declined to chemotherapy/radiotherapy.
- Estimated life expectancy > 3 months.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.
- Age 18 to 80.
- Adequate hematologic function, with WBC ≥ 3000/microliter, hemoglobin ≥ 9 g/dL (it is acceptable to have had prior transfusion), platelets ≥ 75,000/microliter; PT-INR <1.5 (unless patient is receiving warfarin in which case PT-INR must be <3), PTT <1.5X ULN
- Adequate renal and hepatic function, with serum creatinine < 1.5 mg/ dL, bilirubin < 1.5 mg/dL (except for Gilbert's syndrome which will allow bilirubin ≤ 2.0 mg/dL), ALT and AST ≤ 2.5 x upper limit of normal.
Exclusion Criteria:
- Patients with a history of autoimmune disease, such as but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis. Autoimmune related thyroid disease and vitiligo are permitted.
- Patients with serious intercurrent chronic or acute illness, such as cardiac disease (NYHA class III or IV), hepatic disease, or other illness considered by the Principal Investigator as unwarranted high risk for investigational drug treatment.
- Patients with a medical or psychological impediment to probable compliance with the protocol should be excluded.
- Concurrent (or within the last 5 years) second malignancy other than non melanoma skin cancer, cervical carcinoma in situ, controlled superficial bladder cancer, or other carcinoma in situ that has been treated.
- Presence of an active acute or chronic infection including: a urinary tract infection, HIV (as determined by ELISA and confirmed by Western Blot). Patients with HIV are excluded based on immuno-suppression, which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections.
- Patients on chronic steroid therapy (or other immuno-suppressives, such as azathioprine or cyclosporin A) are excluded on the basis of potential immune suppression. Patients must have had 6 weeks of discontinuation of any steroid therapy (except that used as pre-medication for chemotherapy or contrast-enhanced studies or for acute treatment (<5 days) of intercurrent medical condition such as a gout flare) prior to enrollment.
- Pregnant and nursing women should be excluded from the protocol since this research may have unknown and harmful effects on an unborn child or on young children. If the patient is sexually active, the patient must agree to use a medically acceptable form of birth control while receiving treatment and for a period of 4 months following the last vaccination therapy. It is not known whether the treatment used in this study could affect the sperm and could potentially harm a child that may be fathered while on this study.
- Patients with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anti-PD-1 plus DC-CIK
|
Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days.
Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment.
If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
|
Active Comparator: Anti-PD-1 alone
|
Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival of the participants
Time Frame: 12 months
|
From starting date of anti-PD-1 antibody treatment until date of until the date of first documented disease progression or date of death from any cause, whichever comes first.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival of the participants(OS)
Time Frame: 24 months
|
From starting date of anti-PD-1 antibody treatment until date of death from any cause
|
24 months
|
Assessment of Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PROCTCAE)
Time Frame: 24 months
|
To assess and compare the PRO-CTCAE by patients receiving immunotherapy
|
24 months
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 24 months
|
24 months
|
|
Molecular Tumor Burden Index
Time Frame: 24 months
|
Using mutation detection in ctDNA by liquid biopsy to assess tumor dynamics
|
24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cell-free tumor DNA
Time Frame: 24 months
|
To investigate the relationship of ctDNA with clincial outcomes
|
24 months
|
Tumor related antigen peptides
Time Frame: 24 months
|
To investigate the relationship of tumor related antigen peptides with clincial outcomes
|
24 months
|
T cell metaboic activity
Time Frame: 24 months
|
To investigate the relationship of T cell metaboic activity with clincial outcomes
|
24 months
|
Microbial bacteria
Time Frame: 24 months
|
To investigate the relationship of microbial bacteria with clincial outcomes
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2016
Primary Completion (Actual)
December 31, 2022
Study Completion (Actual)
June 1, 2023
Study Registration Dates
First Submitted
November 27, 2017
First Submitted That Met QC Criteria
December 1, 2017
First Posted (Actual)
December 4, 2017
Study Record Updates
Last Update Posted (Estimated)
February 7, 2024
Last Update Submitted That Met QC Criteria
February 5, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- PD-1 plus DC-CIK for NSCLC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
European Association for Endoscopic SurgeryWithdrawn
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong
Clinical Trials on Anti-PD-1 plus DC-CIK
-
Capital Medical UniversityDuke UniversityCompleted
-
Allife Medical Science and Technology Co., Ltd.Beijing Hospital; The First People's Hospital of Yunnan Province/First People... and other collaboratorsUnknown
-
Capital Medical UniversityUnknown
-
Capital Medical UniversityTerminatedCancer | Mesothelioma, MalignantChina
-
Dalian UniversityUnknownNon-small Cell Lung Cancer
-
Affiliated Hospital to Academy of Military Medical...Unknown
-
Affiliated Hospital to Academy of Military Medical...UnknownSmall- Cell Lung Cancer
-
Fuzhou General HospitalUnknownRenal Cell CarcinomaChina
-
Capital Medical UniversityDuke University; Geneplus-Beijing Co. Ltd.Completed
-
Second Military Medical UniversityUnknownAdvanced Hepatocellular CarcinomaChina